Physician profile
Rhea Dean
NPI 1528002946
$4,942.26
in general payments reported to CMS, 2019-2025
39 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $648 · 2021: $785 · 2022: $730 · 2023: $680 · 2024: $694 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,179.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $463.71 | 2021-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.98 | 2019-2025 | Jardiance |
| Amgen INC. | $374.29 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $346.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $311.02 | 2019-2024 | Bexsero, Pediarix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $219.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $178.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.76 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $123.46 | 2023-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $118.10 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $112.57 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.25 | 2021-2023 | |
| Esperion Therapeutics, INC. | $72.74 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $66.46 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhea Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.